Overview

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes

Status:
Terminated

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Jean Perrin

Treatments:

Cisplatin
Cyclophosphamide